TY  - JOUR
T1  - Enhancement of Pioglitazone Hydrochloride Solubility Through Liquisolid Compact Formulation Using Novel Carrier Neusilin US2
A1  - Bhushan Rajendra Rane
A1  - Dnyaneshwar Sopan Gaikwad
A1  - Ashish Suresh Jain
A1  - Prashant Lakshaman Pingale
A1  - Nayan Ashok Gujarathi
JF  - Pharmacophore
JO  - Pharmacophore
SN  - 2229-5402
Y1  - 2022
VL  - 13
IS  - 3
DO  - 10.51847/aJMSk1I0oy
SP  - 64
EP  - 71
N2  - Main objective behind formulating any dosage form is to develop the optimized and stable dosage from which will releae the drug fastly in conventional formulations. Various approaches such as, solid dispersion, crystal engineering, ball milling, complexation, and self-emulsifying drug delivery systems have all been used in recent research to increase the solubility of the drug, but the liquisolid compact has demonstrated superior results for enhancing dissolution. In most of the cases absorption of drug is less which is due to various factors one of the most important factor is drug solubility. Liquisolid compacts are a novel and promising addition to such a novel goal because the liquisolid technology has been successfully used to treat low-dose poorly soluble drugs. A thiazolidinedione, pioglitazone HCl is primarily prescribed to type 2 diabetics as an anti-hyperglycemic medication. Compared to traditional carrier materials, Neusilin US2 performs better as a carrier material in liquisolid compact. Drugs from BCS Class II can be easily formulated using liquisolid compact by the simple blending method. A drug having a low dose can be formulated by this method.
UR  - https://pharmacophorejournal.com/article/enhancement-of-pioglitazone-hydrochloride-solubility-through-liquisolid-compact-formulation-using-no-m7fgcaopdesiuna
ER  -